TargetMol

Lanabecestat camsylate

Product Code:
 
TAR-T25610
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T25610-5mg5mg£1,091.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25610-50mg50mg£2,143.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T25610-100mg100mg£2,801.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Lanabecestat camsylate is used as a BACE1 Inhibitor.
CAS:
1522418-41-2
Formula:
C36H44N4O5S
Molecular Weight:
644.83
Purity:
0.98
SMILES:
[H][C@@]12CC[C@@](CS(O)(=O)=O)(C(=O)C1)C2(C)C.COC1CC[C@]2(Cc3ccc(cc3C22N=C(C)C(N)=N2)-c2cncc(c2)C#CC)CC1

References

1. Sims JR, Selzler KJ, Downing AM, Willis BA, Aluise CD, Zimmer J, Bragg S, Andersen S, Ayan-Oshodi M, Liffick E, Eads J, Wessels AM, Monk S, Schumi J, Mullen J. Development Review of the BACE1 Inhibitor Lanabecestat (AZD3293/LY3314814). J Prev Alzheimers Dis. 2017;4(4):247-254. doi: 10.14283/jpad.2017.38. PubMed PMID: 29181490. 2. Sakamoto K, Matsuki S, Matsuguma K, Yoshihara T, Uchida N, Azuma F, Russell M, Hughes G, Haeberlein SB, Alexander RC, Eketj?ll S, Kugler AR. BACE1 Inhibitor Lanabecestat (AZD3293) in a Phase 1 Study of Healthy Japanese Subjects: Pharmacokinetics and Effects on Plasma and Cerebrospinal Fluid A? Peptides. J Clin Pharmacol. 2017 Nov;57(11):1460-1471. doi: 10.1002/jcph.950. Epub 2017 Jun 15. PubMed PMID: 28618005. 3. Ye N, Monk SA, Daga P, Bender DM, Rosen LB, Mullen J, Minkwitz MC, Kugler AR. Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics. Clin Pharmacol Drug Dev. 2018 Mar;7(3):233-243. doi: 10.1002/cpdd.422. Epub 2018 Jan 10. PubMed PMID: 29319935; PubMed Central PMCID: PMC5947295.